Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.123.013503 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Aditya S Bharadwaj und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Loma Linda University Medical Center, CA (A.S.B.). Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Heart-Assist Devices, Renal Insufficiency, Chronic, Glomerular Filtration Rate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Prior studies have found that patients with chronic kidney disease (CKD) have worse outcomes following percutaneous coronary intervention (PCI). There are no data about patients with advanced CKD undergoing Impella-supported high-risk PCI. We, therefore, aimed to evaluate angiographic characteristics and clinical outcomes in patients with CKD who received Impella-supported high-risk PCI as part of the catheter-based ventricular assist device PROTECT III study (A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump [IABP] in Patients Undergoing Non Emergent High Risk PCI). METHODS: Patients enrolled in the PROTECT III study were analyzed according to their baseline estimated glomerular filtration rate (eGFR). The primary outcome was 90-day major adverse cardiovascular and cerebrovascular events (the composite of all-cause death, myocardial infarction, stroke/transient ischemic attack, and repeat revascularization). RESULTS: Of 1237 enrolled patients, 1052 patients with complete eGFR baseline assessment were evaluated: 586 with eGFR ≥60 mL/min per 1.73 m 2 , 190 with eGFR ≥45 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Loma Linda University Medical Center, CA (A.S.B.).
- Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (A.A.-M., A.S.M., Z.Z., Y.L., B.R.).
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (W.B.B.).
- Department of Cardiology, Northside Hospital Cardiovascular Institute, Atlanta, GA (C.L.G.).
- Massachusetts General Hospital, Boston (S.J.B.).
- Baim Institute for Clinical Research, Boston, MA (S.J.B.).
ORCID-Profile: Aditya S Bharadwaj, Arsalan Abu-Much, Yanru Li, Cindy L Grines, Suzanne J Baron, Björn Redfors, Alexandra J Lansky, Mir B Basir, William W O'Neill
Förderung
- NCATS NIH HHS
Zitieren
APA
Bharadwaj, A. S., Abu-Much, A., Maini, A. S., Zhou, Z., Li, Y., Batchelor, W. B., Grines, C. L., Baron, S. J., Redfors, B., Lansky, A. J., Basir, M. B., & O'Neill, W. W. (2024). Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.123.013503
Vancouver
Bharadwaj AS, Abu-Much A, Maini AS, Zhou Z, Li Y, Batchelor WB, et al. Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013503
BibTeX
@article{Bharadwaj2024,
author = {Bharadwaj, Aditya S and Abu-Much, Arsalan and Maini, Aneel S and Zhou, Zhipeng and Li, Yanru and Batchelor, Wayne B and Grines, Cindy L and Baron, Suzanne J and Redfors, Björn and Lansky, Alexandra J and Basir, Mir B and O'Neill, William W},
title = {Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.123.013503}
}
EUVIMED